Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked
Reference71 articles.
1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372–375.
2. Baxter JE, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycthemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
4. James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function of JAK2 in myeloproliferative disorders. New Engl J Med 2005;352:1779–1790.